Evaluation of cancer drug infusion devices prior to the implementation of a compounding robot.

Antineoplastic agents cancer drugs drug administration infusion device nursing occupational exposure robotization

Journal

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372

Informations de publication

Date de publication:
Mar 2024
Historique:
medline: 18 3 2024
pubmed: 19 5 2023
entrez: 19 5 2023
Statut: ppublish

Résumé

Compounding robots are increasingly being implemented in hospital pharmacies. In our hospital, the recent acquisition of a robot (RIVA The ChemoLock The connection/disconnection test showed that although all the devices complied with the current standard, there was a statistically significant difference in the mean ± standard deviation compression force (51.5 ± 11.6 for the Connect-Z Our results showed that the new infusion device complied with current standards. However, the presence of contamination emphasizes the need for operators to use the recommended personal protective equipment. Further studies of contamination with cancer drugs are required.

Identifiants

pubmed: 37203170
doi: 10.1177/10781552231170792
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

251-256

Déclaration de conflit d'intérêts

Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Guillaume Caron (G)

Institut de Pharmacie, CHU Lille, Lille, France.

Michèle Vasseur (M)

Institut de Pharmacie, CHU Lille, Lille, France.
Université de Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Justin Courtin (J)

Institut de Pharmacie, CHU Lille, Lille, France.

Morgane Masse (M)

Institut de Pharmacie, CHU Lille, Lille, France.
Université de Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Bertrand Décaudin (B)

Institut de Pharmacie, CHU Lille, Lille, France.
Université de Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Stéphanie Genay (S)

Institut de Pharmacie, CHU Lille, Lille, France.
Université de Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Pascal Odou (P)

Institut de Pharmacie, CHU Lille, Lille, France.
Université de Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Nicolas Simon (N)

Institut de Pharmacie, CHU Lille, Lille, France.
Université de Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH